Intraoperative avidination for radionuclide therapy: A prospective new development to accelerate radiotherapy in breast cancer

Clinical Cancer Research

Volumn 13, Issue 18, 2007, Pages

  Paganelli, Giovanni ^a   Ferrari, Mahila ^a   Ravasi, Laura ^a   Cremonesi, Marta ^a   De Cicco, Concetta ^a   Galimberti, Viviana ^a   Sivolapenko, Gregory ^b   Luini, Alberto ^a   De Santis, Rita ^c   Travaini, Laura Lavinia ^a   Fiorenza, Maurizio ^a   Chinol, Marco ^a   Papi, Stefano ^a   Zanna, Claudio ^c   Carminati, Paolo ^c   Veronesi, Umberto ^a  

^a EUROPEAN INSTITUTE OF ONCOLOGY   (Italy)

^b UNIVERSITY OF PATRAS   (Greece)

^c Sigma Tau SpA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

1,4,7,10 TETRAAZACYCLODODECANE 1,4,7,10 TETRAACETIC ACID; 1,4,7,10 TETRAAZACYCLODODECANE 1,4,7,10 TETRAACETIC ACID BIOTIN IN 111; 1,4,7,10 TETRAAZACYCLODODECANE 1,4,7,10 TETRAACETIC ACID BIOTIN Y 90; ALBUMIN; AVIDIN; BIOTIN; INDIUM 111; UNCLASSIFIED DRUG; YTTRIUM 90;

ADULT; BREAST CANCER; CLINICAL ARTICLE; CONFERENCE PAPER; DOSIMETRY; DRUG ABSORPTION; DRUG CLEARANCE; DRUG EXCRETION; DRUG UPTAKE; HUMAN; ISOTOPE LABELING; PEROPERATIVE CARE; PILOT STUDY; PRIORITY JOURNAL; RADIATION DOSE; RADIOISOTOPE THERAPY; SCINTIGRAPHY; SEGMENTAL MASTECTOMY;

ADOLESCENT; ADULT; AGED; AVIDIN; BIOTIN; BRACHYTHERAPY; BREAST NEOPLASMS; COMBINED MODALITY THERAPY; FEMALE; HUMANS; INDIUM RADIOISOTOPES; INJECTIONS, INTRALESIONAL; INJECTIONS, INTRAVENOUS; INTRAOPERATIVE PERIOD; MASTECTOMY, SEGMENTAL; MIDDLE AGED; ORGANOMETALLIC COMPOUNDS; PILOT PROJECTS; PROSPECTIVE STUDIES; RADIOPHARMACEUTICALS; RADIOTHERAPY, ADJUVANT; SENTINEL LYMPH NODE BIOPSY; TISSUE DISTRIBUTION; YTTRIUM RADIOISOTOPES;

EID: 34848872913     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-07-1058     Document Type: Conference Paper

References (37)

1. Luini A, Gatti G, Galimberti V, et al. Conservative treatment of breast cancer: its evolution. Breast Cancer Res Treat 2005;94:195-8.
2. Veronesi U, Cascinelli N, Mariani L, et al. Twenty-year follow-up of a randomized study comparing breast-conservative surgery with radical mastectomy for early breast cancer. N Eng J Med 2002;347:1227-32.
3. Athas WF, Adams-Cameron M, Hunt WC, Amir-Fazli A, Key CR.Travel distance to radiation therapy and receipt of radiotherapy following breast-conserving surgery. J Natl Cancer Inst 2000;92:269-71.
4. Veronesi U, Orecchia R, Luini A, et al. Full-dose intraoperative radiotherapy with electrons during breast-conserving surgery: experience with 590 cases. Ann Surg 2005;242:101-6.
5. Vicini FA, Remouchamps V, Wallace M, et al. Ongoing clinical experience utilizing 3D conformal external beam radiotherapy to deliver partial-breast irradiation in patients with early-stage breast cancer treated with breast-conserving therapy. Int J Radiat Oncol Biol Phys 2003;57:1247-53.
6. Polgar C, Sulyok Z, Fodor J, et al. Sole brachytherapy of the tumor bed after conservative surgery for T1 breast cancer: five year results of a phase 1-2 study and initial finding of a randomized phase 3 trial. J Surg Oncol 2002;80:121-8.
7. Vaidya JS, Tobias JS, Baum M, et al. TARGeted Intraoperative radiotherapy (TARGIT): an innovative approach to partial-breast irradiation. Semin Radiat Oncol 2005;15:84-91.
8. Vicini FA, Baglan KL, Kestin LL, et al. Accelerated treatment of breast cancer. J Clin Oncol 2001;19:1993-2001.
9. Paganelli G, Chinol M. Radioimmunotherapy: is avidin-biotin pretargeting the preferred choice among pretargeting methods? Eur J Nucl Med Mol Imaging 2003;30:773-6.
10. Grana C, Chinol M, Robertson C, et al. Pretargeted adjuvant radioimmunotherapy with yttrium-90-biotin inmalignant glioma patients: a pilot study. Br J Cancer 2002;86:207-12.
11. Goldenberg DM, Sharkey RM, Paganelli G, Barbet J, Chatal JF. Antibody pretargeting advances cancer radioimmunodetection and radioimmunotherapy. J Clin Oncol 2006;24:823-34.
12. Urbano N, Pap i S, Ginanneschi M, et al. Evaluation of a new biotin-dota conjugate for pretargeted antibody guided radioimmunotherapy (PAGRIT®). Eur J Nucl Med Mol Imaging 2007;34:68-77.
13. Cremonesi M, Ferrari M, Chinol M, et al. Three-step radioimmunotherapy with yttrium-90 biotin: dosimetry and pharmacokinetics in cancer patients. Eur J Nucl Med 1999;26:110-20.
14. Siegel JA, Thomas SR, Stubbs JB, et al. Techniques for quantitative radiopharmaceutical biodistribution data acquisition and analysis for use in human radiation dose estimates. MIRD Pamphlet no.16. J Nucl Med 1999;40:S37-61.
15. Foster D, Barret P. Developing and testing integrated multicompartment models to describe a single-input multiple-output study using the SAAM II software system. In: Proc. Sixth International Radiopharmaceutical. Dosimetry Symposium, Oak Ridge Institute for Science and Education, 1998.
16. Stabin MG, Sparks RB, Crowe E. OLINDA/EXM: the second-generation personal computer software for internal dose assessment in nuclear medicine. J Nucl Med 2005;46:1023-7.
17. Sgouros G. Bone marrow dosimetry for radioimmunotherapy: theoretical considerations. J Nucl Med 1993;34:689-94.
18. Thomas SR, Stabin MG, Chin-Tu C, Samaratunga RC. MIRD Pamphlet no. 14: a dynamic urinary bladder model for radiation dose calculations. J Nucl Med 1992;33:783-802.
19. Dale R. Dose-rate effects in targeted radiotherapy. Phys Med Biol 1996;41:1187-4.
20. Dale R. Use of the linear-quadratic radiobiological model for quantifying kidney response in targeted radiotherapy. Cancer Biother Radiopharm 2004;19:363-70.
21. Rosenstein BS, Lymberis SC, Formenti SC. Biologic comparison of partial breast irradiation protocols. Int J Radiat Oncol Biol Phys 2004;60:1393-404.
22. 90Y-DOTATOC: relevance of kidney volume and dose rate in finding a dose-effect relationship. J Nucl Med 2005;46:99-106S.
23. Yao Z, Zhang M, Sakahara H, Saga T, Arano Y, Konishi J. Targeting of interperitoneal tumors with avidin. J Natl Cancer Inst 1998;90:25-9.
24. 111In-biotin scintigraphy in patients with suspected vertebral osteomyelitis. Eur J Nucl Med Mol Imaging 2004;31:1505-11.
25. Samuel A, Paganelli G, Chiesa R, et al. Detection of prosthetic vascular graft infection using avidin/indium-111-biotin scintigraphy. J Nucl Med 1996;37:55-61.
26. Rusckowski M, Paganelli G, Hnatowich DJ, et al. Imaging osteomyelitis with streptavidin and indium-111-labeled biotin. J Nucl Med 1996;37:1655-62.
27. Axworthy DB, Reno JM, Hylarides MD, et al. Cure of human carcinoma xenografts by a single dose of pretargeted yttrium-90 with negligible toxicity. Proc Natl Acad Sci U S A 2000;97:1802-7.
28. 90Y-biotin in glioma patients: phase I study and preliminary therapeutic results. Cancer Biother Radiopharm 2001;16:227-35.
29. Chinol M, De Cobelli O, Trifirò G, et al. Localization of avidin in superficial bladder cancer: a potentially new approach for radionuclide therapy. Eur Urol 2003;44:556-9.
30. Knox SJ, Goris ML, Tempero M, et al. Phase II trial of yttrium-90-DOTA-biotin pretargeted by NR-LU-10 antibody/streptavidin in patients with metastatic colon cancer. Clin Cancer Res 2000;6:406-14.
31. Schubiger PA, Alberto R, Smith A.Vehicles. Chelators, and radionuclides: choosing the "building block" of an effective therapeutic radioimmunoconjugate. Bionconjug Chem1996;7:165-79.
32. Emami B, Lyman J, Brown A, et al. Tolerance of normal tissue to therapeutic irradiation. Int J Radiat Oncol Biol Phys 1991;21:109-22.
33. Kassis AI, Adelstein SJ. Radiobiologic principles in radionuclide therapy. J Nucl Med 2005;46:4-12S.
34. Dale R, Carabe-Fernandez A. The radiobiology of conventional radiotherapy and its application to radionuclide therapy. Cancer Biother Radiopharm 2005;20:47-51.
35. 3-octreotate. J Nucl Med 2005;46:46:46:83-91S.
36. 3-octretide accurate enough to predict thresholds for individual patients ? Cancer Biother Radiopharm 2003;18:619-25.
37. Cremonesi M, Ferrari M, Bodei L, Tosi G, Paganelli G. Dosimetry in peptide radionuclide receptor therapy: a review. J Nucl Med 2006;47:1467-75.